A pneumonia antibiotic is where it's really at, financially, for CFRX; following a wkd conference last spring, in which co's positive results treating pneumonia in vivo were presented, that Monday shares spiked from about $1 to $4 on 6mil volume PREMARKET, suggesting conference attendees - likely pros - were the buyers. Hopefully we'll see some pros start buying here. Dunno.
IMO (shareowner)
News 
Market Data 
Discover 
